VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the stock.

Separately, Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Price Performance

Shares of NYSE VNRX opened at $0.72 on Tuesday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The firm has a 50-day simple moving average of $0.68 and a two-hundred day simple moving average of $0.68. The company has a market cap of $66.72 million, a P/E ratio of -1.80 and a beta of 1.10.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.34 million. As a group, equities research analysts expect that VolitionRx will post -0.31 EPS for the current year.

Insiders Place Their Bets

In other VolitionRx news, Director Guy Archibald Innes bought 150,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were bought at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the acquisition, the director now directly owns 406,683 shares in the company, valued at approximately $272,477.61. The trade was a 58.44 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 12.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.